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Abstract
Rare genetic variants are abundant across the human genome, and identifying their function and 
phenotypic impact is a major challenge. Measuring aberrant gene expression has aided in 
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identifying functional, large-effect rare variants (RVs). Here, we expanded detection of genetically 
driven transcriptome abnormalities by analyzing gene expression, allele-specific expression, and 
alternative splicing from multitissue RNA-sequencing data, and demonstrate that each signal 
informs unique classes of RVs. We developed Watershed, a probabilistic model that integrates 
multiple genomic and transcriptomic signals to predict variant function, validated these predictions 
in additional cohorts and through experimental assays, and used them to assess RVs in the UK 
Biobank, the Million Veterans Program, and the Jackson Heart Study. Our results link thousands 
of RVs to diverse molecular effects and provide evidence to associate RVs affecting the 
transcriptome with human traits.
Graphical Abstract
INTRODUCTION: The human genome contains tens of thousands of rare (minor allele frequency 
<1%) variants, some of which contribute to disease risk. Using 838 samples with whole-genome 
and multitissue transcriptome sequencing data in the Genotype-Tissue Expression (GTEx) project 
version 8, we assessed how rare genetic variants contribute to extreme patterns in gene expression 
(eOutliers), allelic expression (aseOutliers), and alternative splicing (sOutliers). We integrated 
these three signals across 49 tissues with genomic annotations to prioritize high-impact rare 
variants (RVs) that associate with human traits.
RATIONALE: Outlier gene expression aids in identifying functional RVs. Transcriptome 
sequencing provides diverse measurements beyond gene expression, including allele-specific 
expression and alternative splicing, which can provide additional insight into RV functional 
effects.
RESULTS: After identifying multitissue eOutliers, aseOutliers, and sOutliers, we found that 
outlier individuals of each type were significantly more likely to carry an RV near the 
corresponding gene. Among eOutliers, we observed strong enrichment of rare structural variants. 
sOutliers were particularly enriched for RVs that disrupted or created a splicing consensus 
sequence. aseOutliers provided the strongest enrichment signal when evaluated from just a single 
tissue.
We developed Watershed, a probabilistic model for personal genome interpretation that improves 
over standard genomic annotation–based methods for scoring RVs by integrating these three 
transcriptomic signals from the same individual and replicates in an independent cohort.
To assess whether outlier RVs identified in GTEx associate with traits, we evaluated these variants 
for association with diverse traits in the UK Biobank, the Million Veterans Program, and the 
Jackson Heart Study. We found that transcriptome-assisted prioritization identified RVs with larger 
trait effect sizes and were better predictors of effect size than genomic annotation alone.
CONCLUSION: With >800 genomes matched with transcriptomes across 49 tissues, we were 
able to study RVs that underlie extreme changes in the transcriptome. To capture the diversity of 
these extreme changes, we developed and integrated approaches to identify expression, allele-
specific expression, and alternative splicing outliers, and characterized the RV landscape 
underlying each outlier signal. We demonstrate that personal genome interpretation and RV 
discovery is enhanced by using these signals. This approach provides a new means to integrate a 
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richer set of functional RVs into models of genetic burden, improve disease gene identification, 
and enable the delivery of precision genomics. ■
Transcriptomic signatures identify functional rare genetic variation. We identified genes in 
individuals that show outlier expression, allele-specific expression, or alternative splicing and 
assessed enrichment of nearby rare variation. We integrated these three outlier signals with 
genomic annotation data to prioritize functional RVs and to intersect those variants with disease 
loci to identify potential RV trait associations.
Background
The human genome contains tens of thousands of rare [minor allele frequency (MAF) <1%] 
variants (1), some of which contribute to rare and common disease risks (2, 3). However, 
identifying functional rare variants (RVs), especially in the noncoding genome, remains 
difficult because of their low frequency and the lack of a regulatory genetic code. Outlier 
gene expression aids in identifying functional, large-effect RVs (4–8). Furthermore, 
transcriptome sequencing provides diverse measurements beyond gene expression level, 
including allele-specific expression (ASE) and alternative splicing, that have yet to be 
systematically evaluated and integrated into variant effect prediction (9–11).
Using 838 samples with both whole-genome and transcriptome samples in the Genotype-
Tissue Expression (GTEx) project version 8 (v8), we assessed how rare genetic variants 
contribute to outlier patterns in total expression (hereafter referred to simply as 
“expression”), allelic expression, and alternative splicing deep into the allele frequency (AF) 
spectrum. We integrated these three transcriptomic signals across 49 tissues, along with 
diverse genomic annotations to prioritize high-impact RVs, and assessed their relationship to 
complex traits in the UK Biobank (UKBB) (12), the Million Veterans Program (MVP) (13), 
and the Jackson Heart Study (JHS) (14). We further identified dozens of candidate RVs 
influencing well-studied disease genes, including APOE, FAAH, and MAPK3.
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Results
Detection of aberrant gene expression across multiple transcriptomic phenotypes
We quantified three transcriptional phenotypes for each gene to capture a wide range of 
functional effects caused by regulatory genetic variants. Briefly, to identify expression 
outliers (eOutliers), we generated Z scores from corrected expression data per tissue to 
determine whether a gene in an individual has extremely high or low expression (fig. S1) 
(15, 16). To identify genes with excessive allelic imbalance [allele-specific expression (ASE) 
outliers (aseOutliers)] we used ANEVA-DOT (analysis of expression variation–dosage 
outlier test; figs. S2 and S3) (16, 17). This method uses estimates of genetic variation in 
dosage of each gene in a population to identify genes for which an individual has a 
heterozygous variant with an unusually strong effect on gene regulation (17). Splicing 
outliers (sOutliers) were detected using SPOT (splicing outlier detection), an approach 
introduced here that fits a Dirichlet-Multinomial distribution directly to counts of reads split 
across alternatively spliced exon-exon junctions for each gene. SPOT then identifies 
individuals that deviate significantly from the expectation on the basis of this fitted 
distribution (figs. S4 to S6) (16). Each of the three methods was applied across all GTEx 
samples. An individual was called a multitissue outlier for a given gene if its median outlier 
statistic across all measured tissues exceeded a chosen threshold (Fig. 1A) (16). Using this 
multitissue approach for each phenotype, we found that each individual had a median of four 
eOutlier, four aseOutlier, and five sOutlier genes.
Genes with aberrant expression, ASE, and splicing are enriched for functionally distinct 
RVs
We observed that multitissue outliers for any of the three transcriptomic phenotypes were 
significantly more likely to carry a RV (MAF <1%) in the gene body or ±10 kb than 
individuals without outliers, assessed among 714 individuals with European ancestry. These 
enrichments were progressively more pronounced for rarer variants and were stronger for 
structural variants (SVs) than for single-nucleotide variants (SNVs) and indels (Fig. 1B). 
These trends were not reliant on the specific choice of the threshold used to define outliers 
(figs. S7 and S8).
We found only 35 cases in which an individual gene was a multitissue outlier for all three 
transcriptional phenotypes. All but one of these had a nearby RV, and most were annotated 
as splice variants. Among genes that were outliers for two transcriptional phenotypes in an 
individual (n = 465), the greatest overlap occurred between aseOutliers and eOutliers (n = 
319; fig. S9A). We found that aseOutliers with modest expression changes (1 < |median Z| < 
3) showed stronger enrichment for nearby RVs than those without any expression change 
(fig. S9), highlighting an important benefit of combining these phenotypes to discover 
diverse RV effects. We found that genes for which no outlier individuals were identified 
were enriched for Gene Ontology biological process terms relating to sensory perception 
and detection of chemical stimuli for all outlier types (fig. S10) (16), which is consistent 
with enrichments seen for genes that do not have any cis-expression quantitative trait loci 
(eQTLs) discovered in GTEx (18).
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We found that different types of genetic variants contribute to outliers for the three 
molecular phenotypes, although rare splice donor variants were enriched near all outlier 
types (Fig. 1C). The largest differences in variant type enrichment among the three outlier 
types were copy number variations (CNVs) and duplications, which were almost exclusively 
associated with eOutliers, and splice acceptor variants, which were enriched considerably 
more within sOutliers (fig. S11).
For all phenotypes, the proportion of outliers with a nearby RV of any category increased 
with threshold stringency (Fig. 1D). For eOutliers, aseOutliers, and sOutliers, at the strictest 
threshold of median outlier P < 1.1 × 10−7, most individuals were carrying at least one RV 
nearby the outlier gene (82 to 94%). When looking further at RVs with functional 
annotations (from the annotations listed in Fig. 1C), we found that underexpressed eOutliers 
were the most interpretable, with 88% of outlier-associated RVs having an additional 
functional annotation, whereas aseOutliers had the lowest proportion at 56% (Fig. 1D). This 
analysis provides further insight into expectations for causal RV types when an outlier effect 
of a specific magnitude is observed in an individual.
Conversely, a large proportion of genes with nearby rare genetic variants did not appear as 
outliers, even for the most predictive classes such as loss-of-function variants. The largest 
proportion of variants leading to any outlier status were rare splice donor and splice acceptor 
variants, of which only 7.2 and 6.8%, respectively, led to an sOutlier (Fig. 1E and fig. S11). 
Overall, whereas some transcriptomic effects may have been missed, the low frequency with 
which RVs of these classes led to large transcriptome changes reinforces the utility of 
incorporating functional data in variant interpretation even for specific variant classes 
already used in clinical interpretation.
Genomic position of RVs predicts the impact on expression
Although we primarily assessed RVs that occur either within an outlier gene or in a 10-kb 
surrounding window, gene regulation can occur at greater distances (19, 20). Because we 
observed the strongest enrichments for the lowest-frequency variants, we intersected 
singleton variants [(SVs); i.e., those appearing only once in GTEx and SNVs and/or indels 
that do not appear in the Genome Aggregation Database (gnomAD) (21)] with 200-kb-
length windows exclusive of other windows and upstream from outlier genes and compared 
their frequency in outlier versus nonoutlier individuals. SNV enrichments dropped off 
quickly at greater distances from the gene but remained weakly enriched for eOutliers out to 
200 kb. The same was true for rare indels, with enrichment at 200 kb only for sOutliers. SVs 
remained enriched at much longer distances, being enriched 2.33-fold as far as 800 kb to 1 
Mb upstream and up to 600 kb downstream of the gene body (Fig. 2A and fig. S12A).
RVs in promoter regions have been previously linked to outlier expression (5, 15). To extend 
these observations and to assess the types of transcription factor (TF)–binding sites that 
could lead to outliers, we tested enrichment of rare transcription start site (TSS) proximal 
variants in specific TF motifs near under- and over-eOutliers. For under-eOutliers, we saw 
an enrichment of variants in GABP, a TF that activates genes that control the cell cycle, 
differentiation, and other critical functions (22). For over-eOutliers, we saw an enrichment of 
RVs intersecting the E2F4 motif, a TF that has been reported as a transcriptional repressor 
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(23). In both under- and over-eOutliers, we saw RVs in YY1, which can act as either an 
activator or repressor, depending on context (24), and has been associated with GABP in 
coregulatory networks (Fig. 2B and fig. S12B) (25). Thus, these naturally occurring RV 
perturbations can provide information about how specific TFs can strongly up- or down-
regulate their target genes.
RVs can affect multiple genes and lead to new gene fusion
We observed that RVs can also affect multiple genes in an individual. We found a strong 
enrichment for multigene effects among eOutliers and, to a lesser degree, aseOutliers (fig. 
S13). As expected, we did not see enrichment for nearby sOutlier pairs, which are less 
subject to coregulation (26). Within a 100-kb window, neighboring eOutlier genes were 70 
times more frequent than would be expected by chance if drawing outlier pairs at random. 
They were also significantly enriched for rare CNVs, duplications, and TSS variants nearby 
one or both genes compared with individuals who had outlier expression but for only one of 
the genes (fig. S13). We also found that rare SV enrichments were present near eOutliers 
regardless of whether the SV overlapped the gene itself (fig. S14). We observed 27 examples 
of rare SVs, including deletions, duplications, and break ends, associated with eOutliers in at 
least two genes in the same individual (fig. S15 and table S1). For one of these, we observed 
evidence of a fusion transcript resulting from a deletion spanning the end of the gene 
SPTBN1 and the TSS of EML6. This deletion led to underexpression of SPTBN1 (median Z 
score = −4.67) and overexpression of EML6 (median Z score = 8.12) compared with all 
other individuals. Supporting the presence of a new germline fusion transcript, we found 
evidence of a specific transcript spanning both SPTBN1 and EML6 in multiple tissues for 
the individual with the deletion (fig. S16). For both of these genes, this individual also 
showed sOutlier signal (median SPOT P = 0.0005 for EML6 and 0.0035 for SPTBN1). The 
identification of fusion transcripts has been of particular interest in cancer diagnosis and 
prognosis (27–30), and both EML genes and SPTBN1 have been previously implicated in 
cancer-associated fusions (31, 32).
RVs in splicing consensus sequence drive splicing outliers
Previous studies have shown RVs disrupting splice sites result in outlier alternative splicing 
patterns (33, 34). We used sOutlier calls made for each LeafCutter cluster (16, 35) to assess 
enrichment of splicing-related variants more precisely. We observed extreme enrichment of 
RVs near splice sites in sOutliers. An sOutlier was 333 times more likely than a nonoutlier 
to harbor a RV within a 2-bp window around a splice site (fig. S17A) (16), with signal 
decaying at greater distances but still enriched up to 100 bp away (relative risk = 7.43). To 
obtain base pair resolution enrichments, we computed the relative risk of sOutlier RVs 
located at specific positions relative to observed donor and acceptor splice sites (16). Ten 
positions near the splice site showed significant enrichment for RVs in sOutliers compared 
with controls (Fig. 2, C and D). These positions corresponded precisely to positions that 
have also been shown to be intolerant to mutations because of their conserved role in 
splicing (we will refer to these positions as the splicing consensus sequence) (34). Among 
the most enriched positions within the splicing consensus sequence were the four essential 
splice site positions (D + 1, D + 2, A − 2, A − 1) (36), which showed an average relative risk 
of 195.
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sOutliers further captured the transcriptional consequences both for variants that disrupted a 
reference splicing consensus sequence and those that created a new splicing consensus 
sequence. Individuals with sOutlier variants in which the rare allele deviated away from the 
splicing consensus sequence showed decreased junction usage of the splice site near the 
variant, whereas individuals with variants in which the rare allele created a splicing 
consensus sequence showed increased junction usage of the splice site near the variant 
relative to nonoutliers (Fig. 2E and figs. S17B and S18) (16). We saw a related enrichment 
pattern after separating annotated and new (unannotated) splice sites (fig. S19). sOutliers 
were also enriched for RVs positioned within the polypyrimidine tract (PPT), a highly 
conserved, pyrimidine-rich region, ~5 to 35 bp upstream from acceptor splice sites (37). A 
RV was 6.25 times more likely to be located in the PPT near an sOutlier relative to a 
nonoutlier. sOutliers with a RV that changed a position in the PPT from a pyrimidine to a 
purine (i.e., disrupting an existing PPT) showed decreased junction usage of the splice site 
near the variant, whereas the inverse was true for variants that changed a position in the PPT 
from a purine to pyrimidine (Fig. 2F and fig. S20).
RVs in tissue-specific regulatory regions can lead to tissue-specific outlier expression
Although multitissue outliers offer improved power to detect RV effects, we also evaluated 
RVs from outliers detected in individual tissues. Single-tissue measurements are subject to 
greater variation than repeat measurements across tissues but are representative of most 
experimental designs. First, we performed replication analysis across all individuals with 
data available for the three methods to evaluate the degree to which outlier status detected in 
one tissue of an individual was replicated in other tissues (16). On average, we found that 
eOutlier, aseOutlier, and sOutlier status in a discovery tissue was detected in a test tissue 5.1, 
10.7, and 8.7% of the time, respectively (Fig. 3A and fig. S21). This is consistent with other 
findings that measurements of ASE are more consistent across tissues (18). Considering 
clinically accessible tissues, namely whole blood, fibroblasts, and lymphoblastoid cells, if 
we consider outliers observed for a gene in at least two of these tissues in the same 
individual, we saw average replication rates across all other tissues of 14.1, 20.9, and 15.0% 
for eOutliers, aseOutliers, and sOutliers, respectively (fig. S22). Both the higher replication 
rate for aseOutliers and the increase in outlier replication in non-accessible tissues when 
considering more than one accessible measurement are informative for the analysis of 
functional data from easily accessible tissues to understand disease states most relevant to 
other tissues.
We next evaluated the ability of single-tissue outliers from each method to prioritize RVs 
near outlier genes. Single-tissue aseOutliers were most enriched for nearby RVs, followed 
by sOutliers and then eOutliers, across all outlier cutoff thresholds (Fig. 3B and fig. S21 and 
S23A). We also observed enrichment of variants likely triggering nonsense-mediated decay 
among single-tissue eOutliers, aseOutliers, and sOutliers (Fig. 3C and fig. S23B). 
Additionally, we found that single-tissue sOutliers still showed strong enrichment for RVs in 
the splicing consensus sequence and the PPT (fig. S24).
Except for rare SVs that notably were enriched at comparable thresholds to multitissue 
eOutliers, single-tissue eOutliers show far weaker enrichments relative to multitissue outliers 
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for nearby rare SNVs and indels across all thresholds (fig. S25). To improve discovery of 
tissue-specific outliers, we leveraged the breadth of tissue data available and used observed 
patterns of correlation across tissues to detect outliers that deviate from the expected 
covariance of expression in a subset of tissues (16). A similar approach has been 
implemented to identify functional RVs on the basis of the correlation of expression among 
genes in a single tissue (5). We found that outliers identified using this approach were often 
driven by expression changes in one or a few tissues compared with multitissue eOutliers 
based on median Z scores (Fig. 3D). The correlation tissue-specific outliers were also 
enriched for nearby RVs in a 10-kb window around the gene (fig. S26C). However, these 
outliers were also enriched for RVs in enhancers that were active in the tissue(s) driving the 
outlier effect (table S2), as determined by single-tissue Z score and within a 500-kb window 
around the gene (Fig. 3E). Notably, these tissue-specific outliers were depleted for rare 
variation in enhancers annotated in other, unmatched tissues.
Prioritizing RVs by integrating genomic annotations with diverse personal transcriptomic 
signals
To incorporate diverse transcriptome signals into a method to prioritize RVs, we developed 
Watershed, an unsupervised probabilistic graphical model that integrates information from 
genomic annotations of a personal genome (table S3) with multiple signals from a matched 
personal transcriptome. Watershed provides scores that can be used for personal genome 
interpretation or for cataloging potentially impactful rare alleles, quantifying the posterior 
probability that a variant has a functional effect on each transcriptomic phenotype based on 
both whole-genome–sequencing (WGS) and RNA-sequencing (RNA-seq) signals (Fig. 4A). 
The Watershed model can be adapted to any available collection of molecular phenotypes, 
including different assays, different tissues, or different derived signals. Further, Watershed 
automatically learns Markov random field (MRF) edge weights reflecting the strength of the 
relationship between the different tissues or phenotypes included that together allow the 
model to predict functional effects accurately.
We first applied Watershed to the GTEx v8 data using the three outlier signals examined 
here, expression, ASE, and splicing (Fig. 4A) (16), for which each was first aggregated by 
taking the median across tissues for the corresponding individual. In agreement with existing 
evidence of similarity between outlier signals (fig. S9), the learned Watershed edge 
parameters were strongest between ASE and expression, followed by ASE and splicing, but 
strictly positive for all pairs of outlier signals (i.e., each outlier signal was informative of all 
other signals; Fig. 4B). To evaluate our model, we used held-out pairs of individuals that 
shared the same RV, making Watershed predictions in the first individual and evaluating 
those predictions using the second individual’s outlier status as a label (15, 16). Watershed 
outperforms methods based on genome sequence alone [our genomic annotation model 
(GAM) and combined annotation-dependent depletion (CADD); Fig. 4C and fig. S27] (38, 
39). We also compared performance of Watershed with RIVER [RNA-informed variant 
effect on regulation (15)], a simplification of the Watershed model in which each outlier 
signal is treated independently. We found that explicitly modeling the relationship between 
different molecular phenotypes provided a performance gain for Watershed (Fig. 4D, figs. 
S28 and S29, and table S4) (16). We observed that even the most predictive genomic 
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annotations only resulted in eOutliers, aseOutliers, and sOutliers 2.8, 7.9, and 14.3% of the 
time, respectively (Figs. 1E and 4C). However, integrating transcriptomic signals with 
genomic annotations from Watershed (at a posterior threshold of 0.9) detected SNVs that 
resulted in eOutliers, aseOutliers, and sOutliers with greater frequency 11.1, 33.3, and 
71.4% of the time, respectively (Fig. 4C and fig. S30).
We further extended the Watershed framework to prioritize variants on the basis of their 
predicted tissue-specific impact. We trained three “tissue-Watershed” models (one for each 
of expression, ASE, and splicing separately), in which each model considers the effects in 
all tissues jointly, sharing information in the MRF, and ultimately outputs 49 tissue-specific 
scores for each RV (figs. S29 and S31) (16). We observed that the parameters learned for 
each of the three tissue-Watershed models resembled known patterns of tissue similarity 
(Fig. 4E and fig. S32) (18). Further, using held-out individuals, the tissue-Watershed model 
outperformed a RIVER model in which each tissue is treated completely independently (P = 
2.00 × 10−5, P = 2.00 × 10−5, and P = 5.90 × 10−3 for expression, ASE, and splicing, 
respectively; one-sided binomial test; Fig. 4F and figs. S33 and S34) and a collapsed RIVER 
model trained with single median outlier statistics (P = 0.0577, P = 0.251, and P = 0.00128 
for expression, ASE, and spicing, respectively; one-sided binomial test; figs. S35 and 36). 
Critically, integrative models that incorporated transcriptomic signal and genomic 
annotations from a single tissue still outperformed methods based only on genome sequence 
annotations (Fig. 4F), supporting the benefit of collecting even a single RNA-seq sample to 
improve personal genome interpretation.
Replication and experimental validation of predicted RV transcriptome effects
We first assessed the replication of “candidate causal RVs” previously identified by the 
SardiNIA Project (6), using GTEx Watershed prioritization. Of five SardiNIA candidate 
causal RVs that were also present in a GTEx individual, four had high (>0.7) GTEx 
Watershed expression posterior probabilities (table S5). Next, we tested replication of GTEx 
RVs, prioritized by Watershed, in an independent cohort evaluating 97 whole-genome and 
matched transcriptome samples from the Amish Study of Major Affective Disorders 
(ASMAD) (40). We evaluated GTEx RVs also present in this cohort at any frequency, 
quantifying eOutlier, aseOutlier, and sOutlier signal in each ASMAD individual harboring 
one of the GTEx variants (16). For all three phenotypes, ASMAD individuals with variants 
having high (>0.8) Watershed posterior probability based on GTEx data had significantly 
more extreme outlier signals at nearby genes compared with individuals with variants having 
low (<0.01) GTEx Watershed posterior probability (expression: P = 2.729 × 10−6, ASE: P = 
2.86 × 10−3, and splicing: P = 5.86 × 10−13; Wilcoxon rank-sum test; fig. S37). Every 
variant with a high GTEx Watershed splicing posterior probability (>0.8) resulted in an 
sOutlier (P ≤ 0.01) in the ASMAD cohort. Furthermore, ASMAD individuals with variants 
having high (>0.8) GTEx Watershed posterior probability had significantly larger outlier 
signals relative to equal size sets of variants prioritized by GAM (expression: P = 0.00129, 
ASE: P = 0.0287, and splicing: P = 0.00058; Wilcoxon rank-sum test; fig. S37). Overall, 
RVs prioritized by Watershed using GTEx data displayed evidence of functional effects in 
ASMAD individuals.
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We further applied both a massively parallel reporter assay (MPRA) and a CRISPR-Cas9 
assay to assess the impact of Watershed-prioritized RVs. We experimentally tested the 
regulatory effects of 52 variants with moderate Watershed expression posterior (≥0.5) and 98 
variants with low Watershed expression posterior (<0.5) using MPRA (16). We observed 
increased effect sizes for RVs with high Watershed expression posterior relative to variants 
with low expression posterior (P = 0.025; one-sided Wilcoxon rank-sum test; fig. S38 and 
table S6). Next, we assessed the functional effects of 20 variants by editing them into 
inducible-Cas9 293T cell lines. These included 14 rare stop-gained variants and six non-
eQTL common variants as negative controls. Of the 14 rare stop-gained variants, 13 had 
expression or ASE Watershed posterior >0.8, with the remaining variant [previously tested 
in (41)] having a posterior of 0.22. All control variants had Watershed posteriors <0.03. Of 
the 13 variants with a Watershed posterior >0.8, 12 showed a significant decrease in 
expression of the rare allele (P < 0.05, Bonferroni corrected; fig. S39 and table S7) (16).
Aberrant expression informs RV trait associations
We found that each individual had a median of three eOutliers, aseOutliers, and sOutliers 
(median outlier P < 0.0027) with a nearby RV. When filtering by moderate Watershed 
posterior probability (>0.5) of affecting expression, ASE, or splicing, individuals had a 
median of 17 genes with RVs predicted to affect expression, 27 predicted to affect ASE, and 
nine predicted to affect splicing (Fig. 5A). From the set of outlier calls, we found multiple 
instances of RVs influencing well-known and well-studied genes, including APOE and 
FAAH (table S8). In particular, for APOE, which has been associated with numerous 
neurological diseases and psychiatric disorders (42), we found two aseOutlier individuals 
both carrying a rare, missense variant, rs563571689, with ASE Watershed posteriors >0.95, 
not previously reported. For FAAH, which has been linked to pain sensitivity in numerous 
contexts (43, 44), we found two eOutlier individuals with a rare 5′ untranslated region 
variant, rs200388505, with ASE and expression Watershed posteriors >0.9.
To assess whether identified rare functional variants from GTEx associate with traits, we 
intersected this set with variants present in the UKBB (12). We focused on a subset of 34 
traits for which GWAS association for a UKBB trait had evidence of colocalizations with 
eQTLs and/or alternative splicing QTLs (sQTLs) in any tissue (table S9) (16, 45). GTEx has 
demonstrated that genes with RV associations for a trait are strongly enriched for their 
eQTLs colocalizing with GWAS signals for the same trait (18), indicating that QTL 
evidence can be used to guide RV analysis. Furthermore, RVs near GTEx outliers had larger 
trait association effect sizes than background RVs near the same set of genes in the UKBB 
data (P = 3.51 × 10−9; one-sided Wilcoxon rank-sum test), with a shift in median effect size 
percentile from 46 to 53%. Notably, outlier variants that fell in or nearby genes with an 
eQTL or sQTL colocalization had even larger effect sizes (median effect size percentile 
88%) than nonoutlier variants (P = 1.93 × 10−5; one-sided Wilcoxon rank-sum test) or 
outlier variants falling near any gene not matched to a colocalizing trait (P = 4.88 × 10−5; 
one-sided Wilcoxon rank-sum test; Fig. 5B).
Although most variants tested in UKBB had low Watershed posterior probabilities of 
affecting the transcriptome (fig. S40A), we hypothesized that filtering for those variants that 
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do have high posteriors would yield variants in the upper end of the effect size distribution 
for a given trait. For each variant tested in UKBB, we took the maximum Watershed 
posterior per variant and compared this with a genomic annotation-defined metric, CADD 
(38, 39). We found that Watershed posteriors were a better predictor of variant effect size 
than CADD scores for the same set of RVs in a linear model (Table 1). Across different 
Watershed posterior thresholds, we found that the proportion of variants falling in the top 
25% of RV effect sizes in colocalized regions exceeded the proportion expected by chance 
(Fig. 5C). Whereas filtering by CADD score did return some high effect size variants, this 
proportion declined at the highest thresholds (fig. S40D). Furthermore, there was very little 
overlap between variants with high Watershed posteriors and high CADD variants (fig. 
S40D), with CADD variants more likely to occur in coding regions and Watershed variants 
more frequent in noncoding regions (fig. S40D). Thus, the approaches largely identified 
distinct and complementary sets of variants for these traits.
We identified 33 rare GTEx variant trait combinations in which the variant had a Watershed 
posterior >0.5 and fell in the top 25% of variants by effect size for the given trait (table S10). 
We highlight two such examples, for asthma and high cholesterol (Fig. 5, D and E), showing 
that although RVs usually do not have the frequency to obtain genome-wide significant P 
values, when they are prioritized by the probability of affecting expression, we could 
identify those with greater estimated effect sizes on the trait (table S11). In the case of 
asthma, the RV effect sizes in UKBB were three times greater than the lead colocalized 
variant. These variants included rs146597587, which is a high-confidence loss-of-function 
splice acceptor with an overall gnomAD AF of 0.0019, and rs149045797, an intronic variant 
with a frequency of 0.0019, both of which were associated with the gene IL33, the 
expression of which has been implicated in asthma (46, 47). Previous work has identified the 
protective association between rs146597587 and asthma (48, 49), and we found that this is 
potentially mediated by outlier allelic expression of IL33 leading to moderate decreases in 
total expression, with median Z scores ranging from −1.08 to −1.77 in individuals with the 
variant, and median single-tissue Z scores across the six individuals exceeding −2 in 10 
tissues. An asthma association had also been reported recently for the other high Watershed 
asthma-associated variant rs149045797 and was in perfect linkage disequilibrium with 
rs146597587 (50). An additional high Watershed variant, rs564796245, an intronic variant in 
TTC38 with a gnomAD AF of 0.0003, had a high effect size for self-reported high 
cholesterol in the UKBB but was not previously reported. We were able to test this variant 
against four related blood lipids traits in the MVP (51). We found that for these traits, which 
included high-density lipoprotein (HDL), low-density lipoprotein, total cholesterol, and 
triglycerides, among rare (gnomAD AF <0.1%) variants within a 250-kb window of 
rs564796245, this variant was in the top 5% of variants by effect size; for HDL specifically, 
it was in the top 1% (fig. S41). We also assessed this variant’s association with the same four 
traits in the JHS (14), an African American cohort in which four individuals carried the RV. 
Here, we found that the direction of effect was consistent with MVP and UKBB for all four 
traits (tables S11 and S12), and the variant fell in the top 28th to 38th percentile of all rare 
(gnomAD AF <0.1%) variants in this region (fig. S42). Only four of the variants tested in 
UKBB had Watershed posterior probabilities >0.9 for colocalized genes, but of those, three 
showed high effect sizes for a relevant trait (table S10).
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Discussion
RVs are abundant in human genomes, yet they have remained difficult to study 
systematically. Using multitissue transcriptome and whole-genome data from GTEx v8, we 
have been able to identify and assess the properties of RVs, including SVs, that underlie 
extreme changes in expression, alternative splicing, and ASE.
We observed that each signal informs distinct classes of RVs, demonstrating the benefit of 
integrating multiple sources of personal molecular data to improve variant interpretation. We 
expanded characterization of the properties of RVs in multiple contexts, including structural 
variants affecting multiple genes, rare splice variants that disrupt or create splicing 
consensus sequences, and RVs occurring in tissue-specific enhancers leading to tissue-
specific eOutliers. Together, these provide a map of the properties of large-effect RVs, aiding 
their identification and evaluation in future studies. We note that although our approach can 
be used to identify some large-effect RVs underlying disease, it is unlikely to capture the full 
spectrum of functional RVs contributing to heritability because some effects will not 
manifest as clear transcriptome aberrations (8).
We further developed a probabilistic model for personal genome interpretation, Watershed, 
which improves standard methods by integrating multiple transcriptomic signals from the 
same individual. Relevant to ongoing efforts to identify RVs affecting human traits, we 
found that in RVs within trait-colocalized regions, filtering by Watershed posteriors can 
identify variants with larger trait effect sizes better than relying on genomic annotations 
alone. As further demonstrated by our discovery of outlier RVs in well-studied disease 
genes, application of Watershed and other integrative methods will prove increasingly 
helpful for cataloging and prioritizing RVs affecting traits, especially those at the lowest 
ends of the AF spectrum. Our results provide a means to improve the quality and extent of 
RV prioritization, with potential future impacts enhancing RV association testing and disease 
gene identification.
Materials and methods summary
Detailed materials and methods are available in the supplementary materials. Briefly, we 
used RNA-seq and WGS data from the v8 release of the GTEx project, which contains 49 
biological tissues with at least 70 samples per tissue.
For the set of RVs analyzed, we retained all SNVs and indels that passed quality control in 
the GTEx v8 variant call format file using the hg38 genome build. Structural variants were 
called on the subset of individuals available in the GTEx v7 release. We defined RVs as 
those with <1% MAF within GTEx and, for SNVs and indels, also occurring at <1% 
frequency in non-Finnish Europeans within gnomAD (21). Annotation of protein-coding 
regions and TF-binding site motifs was generated by running Ensembl VEP (v88).
We next used the RNA-seq data to make outlier calls in each tissue. Briefly, we log2-
transformed the expression values [log2(TPM + 2)], where TPM is the number of transcripts 
per million mapped reads, restricted to lincRNA and protein-coding genes with at least six 
reads and TPM >0.1 in at least 20% of individuals. We scaled the expression of each gene to 
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mean of 0 and a standard deviation of 1 to avoid the deflation of outlier values caused by 
quantile normalization. We corrected for hidden factors using PEER [probabilistic 
estimation of expression residuals (52)] to account for unmeasured technical confounders, as 
well as the top three genotype principal components, sex, and the genotype of the strongest 
cise-QTL per gene in each tissue. We rescaled the residual values per gene and used the 
resulting corrected Z scores to determine eOutliers.
ASE outlier calls in a single tissue were made using ANEVA-DOT to identify genes in each 
individual that showed excessive allelic imbalance of ASE relative to the population. Briefly, 
ANEVA-DOT relies on tissue-specific estimates of genetic variation in gene dosage, VG, 
derived by ANEVA on a reference population’s ASE data to identify genes in individual test 
samples that are likely affected by RVs with unusually large regulatory effects.
Splicing outlier calls were made in a single tissue using SPOT to identify genes in each 
individual that show abnormal splicing patterns. Briefly, For a given LeafCutter cluster in a 
given tissue, we defined a matrix, X (dim NxJ), where each row corresponds to one of N 
samples, each column corresponding to one of J exon-exon junctions mapped to the 
LeafCutter cluster, and each element was the number of raw split read counts corresponding 
to that row’s sample and that column’s exon-exon junction. We were able to compute a P 
value representing how abnormal a given sample’s splicing patterns were for the given 
LeafCutter cluster as follows:
1. Fitted parameters of Dirichlet-Multinomial distribution based on observed data X 
to capture the distribution of split read counts mapping to this LeafCutter cluster;
2. Used the fitted Dichlet-Multinomial distribution to compute the Mahalanobis 
distance for each of the N samples; and
3. Computed the Mahalanobis distance for 1,000,000 samples simulated from the 
fitted Dirichlet-Multinomial distribution and used these 1,000,000 Mahalanobis 
distances as an empirical distribution to assess the significance of the N real 
Mahalanobis distances.
To generate multitissue outlier calls for each gene and outlier type, we calculated an 
individual’s median outlier score across all tissues for which data were available, restricting 
the analysis to individuals with measurements in at least five tissues. To account for 
situations in which widespread extreme expression might occur in an individual because of 
nongenetic influences, we excluded individuals in whom the proportion of tested genes that 
were multitissue outliers, at a P-value threshold of 0.0027, exceeded 1.5 times the 
interquartile range of the distribution of proportion of outlier genes across all individuals.
For the correlation-aware outlier calls, we determined a subset of individuals and tissues 
with <75% missingness, leading to 762 individuals and 29 tissues. We imputed missing 
expression values to improve our estimate of the tissue-by-tissue covariance matrix per gene 
that would be used in outlier calling. We used K-nearest neighbors in the impute R package 
(53) with k = 200 to impute values for missing tissues per individual on a gene-by-gene 
basis. From the imputed matrix, we estimated the tissue covariance matrix for each gene. We 
calculated the Mahalanobis distance for each gene-individual pair and assigned a P value to 
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each gene individual from the chi-squared distribution, with degrees of freedom equal to the 
number of tissues available for that individual.
Watershed is a hierarchical Bayesian model that predicts the regulatory effects of RVs on a 
specific outlier signal based on the integration of multiple transcriptomic signals along with 
genomic annotations describing the RVs. Watershed models instances of gene-individual 
pairs to predict the regulatory effects of RVs nearby the gene. The Watershed model for a 
particular gene-individual pair, assuming K outlier signals, consists of three layers (Fig. 4A):
1. A set of variables G, representing the P observed genomic annotations 
aggregated over all RVs in the individual that are nearby the gene.
2. A set of binary latent variables Z = Z1, …, ZK representing the unobserved 
functional regulatory status of the RVs on each of the K outlier signals.
3. A set of categorical nodes E = E1, …, EK representing the observed outlier status 
of the gene for each of the K outlier signals.
A fully connected conditional random field (CRF) is defined over variables Z given G. 
Variables Ei are each connected only to the corresponding latent variable Zi. Specifically, the 
following conditional probability distributions together define the full Watershed model:
• Z|G ~ CRF(α, β1, …, βk, θ)
• Ek|Zk ~ Categorical(ϕk) ∀ k ∈ K
• ϕk ~ Dirichlet(C, …,C)
• βk Normal 0,
1
λ
where βk ∈ RP ∀ k ∈ K are the parameters defining the contribution of the genomic 
annotations to the CRF for each outlier signal (k), α ∈ RK are the parameters defining the 
intercept of the CRF for each outlier signal (k), θ ∈ R(Kchoose2) are the parameters defining 
the edge weights between pairs of outlier signals, ϕk ∀ k ∈ K are the parameters defining the 
categorical distributions of each outlier signal, and C and λ are hyperparameters of the 
model.
For the CRISPR assay, we selected 14 rare stop-gained variants that were good candidates, 
eight of which passed quality control through (1) filtering to rare stop-gained variants with 
expression and ASE watershed posterior >0.9, (2) filtering to multitissue outlier status in 
both, and (3) keeping four remaining candidates that lie in complex trait genes and the next 
10 with the highest individual outlier signal and Watershed posterior. Variants were tested 
using the polyclonal editing assay described in (41). Briefly, inducible-Cas9 293T cells were 
transfected with a guide RNA and a single-stranded homologous template specific to each 
variant. After sequencing, the effect size was calculated as log2[(Alt/Ref in cDNA)/(Alt/Ref 
in gDNA)] (54). These results were combined with six previously tested stop-gained and six 
non-eQTL control variants for which Watershed posteriors were available.
For the MPRA, we designed a set of synthetic DNA fragments by retrieving the genomic 
sequence corresponding to a 150-bp window centered at each variant of interest for the set of 
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eOutlier-associated RVs and controls. For each variant, a reference and alternative sequence 
was designed that corresponded to each allele. GM12878 cells were cultured, electroporated, 
and collected. MPRA plasmid library construction proceeded as described in (55). To 
assemble oligo-barcode pairings, we merged all paired-end reads using FLASH2 (56), 
requiring a minimum 10-bp overlap to retain each pair. Sequences corresponding to genomic 
fragments were mapped using STAR (57) against a reference assembled using the designed 
oligo library sequences. To count reads per individual barcode sequence, we took raw single-
end reads, extracted the 20-bp region corresponding to the random barcode, and counted the 
number of reads per individual sequence. Finally, to generate oligo-level read counts, we 
computed the sum of all barcodes for each oligo within each sample. We used negative 
binomial regression with an interaction term, implemented using DESeq2 (58), to identify 
significant allele-independent and allele-dependent regulatory effects.
To connect outlier-associated RVs to traits, we assessed genome-wide association study 
(GWAS0 summary statistics from the UKBB phase 2, made available by the Neale 
laboratory (www.nealelab.is/uk-biobank/). We subsetted the variants, either genotyped or 
imputed, in UKBB phase 2 to those that also appeared in any GTEx individuals with a 
frequency of <1% in GTEx, resulting in 45,415 SNVs. We filtered the set of GTEx RVs in 
UKBB to those in trait-colocalized regions, defined as being in a colocalized gene or within 
a 10-kb window. Colocalization calls are detailed in (45).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Enrichment of RVs underlying aberrant expression, splicing, and ASE.
(A) RNA-seq data in 838 individuals were combined across 49 tissues and used to identify 
shared tissue expression, ASE, and alternative splicing outliers. (B) Relative risk of new (not 
in gnomAD), singleton, doubleton, rare (MAF <1%), and low-frequency (MAF 1 to 5%) 
variants in a 10-kb window around the outlier genes across all data types compared with 
nonoutlier individuals for the same genes. Outliers were defined as those with values >3 SDs 
from the mean (|median Z| > 3) or, equivalently, a median P < 0.0027. Bars represent the 
95% confidence interval. (C) Assigning each outlier its most consequential nearby RV, the 
relative risk for different categories of RVs falling within 10 kb of each outlier type. The 
inset panel shows enrichments for a subset of variant categories on a log(2)-transformed y-
axis scale for better visibility. (D) Proportion of outliers at a given threshold that have a 
nearby RV in the given category. eOutlier |median Z scores| were converted to P values using 
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the cumulative probability density function for the normal distribution. TE, transposable 
element; INV, inversion; BND, break end; DEL, deletion; DUP, duplication. (E) Proportion 
of RVs in a given category that lead to an outlier at a P-value threshold of 0.0027 across 
types.
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Fig. 2. RV enrichments in specific genomic positions.
(A) Relative risk of SNVs and indels (not found in gnomAD), and SVs (singleton in GTEx) 
at varying distances upstream of outlier genes (bins exclusive) across data types. (B) 
Proportion of eOutliers with TSS RVs in promoter motifs within 1000 bp. Under and over 
bins are defined with a median Z score threshold of 3, and controls are all individuals with a 
median Z score <3 for the same set of outlier genes. (C) Graphic summarizing positional 
nomenclature relative to observed donor and acceptor splice sites. (D) Relative risk (y-axis) 
of an sOutlier (median LeafCutter cluster P < 1 × 10−5) RV being located at a specific 
position relative to the splice site (x-axis) compared with nonoutlier RVs. Relative risk 
calculation was done separately for donor and acceptor splice sites. (E) Independent position 
weight matrices showing mutation spectra of sOutlier (median LeafCutter cluster P < 1 × 
10−5) RVs at positions relative to splice sites with negative junction usage (i.e., splice sites 
used less in outlier individuals than in nonoutliers). (F) Junction usage of a splice site is the 
natural log of the fraction of reads in a LeafCutter cluster mapping to the splice site of 
interest in sOutlier (median LeafCutter cluster P < 1 × 10−5) samples relative to the fraction 
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in nonoutlier samples aggregated across tissues by taking the median (16). Junction usage 
(y-axis) of the closest splice sites to RVs that lie within a polypyrimidine tract (A − 5, A − 
35) binned by the type of variant (x-axis).
Ferraro et al. Page 27
Science. Author manuscript; available in PMC 2020 November 06.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Fig. 3. Single-tissue outlier enrichments and replication.
(A) Median replication of outliers identified per tissue across every other tissue for each 
outlier type. (B) Relative risk point estimate for nearby rare SNVs for outliers across all 
tissues individually. (C) Relative risk enrichments for likely gene disrupting RVs nearby 
single-tissue outliers at a threshold of |Z| > 4 (equivalently SPOT or ANEVA-DOT P < 
0.000063), with one point per tissue. (D) Distribution of number of tissues with aberrant 
expression underlying expression outliers defined by median Z score (eOutliers) or 
Mahalanobis distance P value (correlation). (E) Relative risk of correlation outliers driven by 
a single tissue, defined as significant correlation outliers for which an expression change of 
the degree indicated by the point color is observed in only a single tissue (16) carrying a RV 
in enhancers annotated to that tissue within a 500-kb window of the outlier gene. Unmatched 
are defined as all tissue-specific enhancer regions regardless of outlier tissue.
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Fig. 4. Prioritizing functional RVs with Watershed.
(A) Graphic summarizing plate notation for the Watershed model when it is applied to three 
median outlier signals (expression, ASE, and splicing). (B) Symmetric heatmap showing 
learned Watershed edge parameters (weights) between pairs of outlier signals after training 
Watershed on three median outlier signals. (C) The proportion of RVs with Watershed 
posterior probability >0.9 (right) and with GAM probability greater than a threshold set to 
match the number of Watershed variants for each outlier signal (left) that lead to an outlier at 
a median P-value threshold of 0.0027 across three outlier signals (colors). Watershed and 
GAM models were evaluated on held-out pairs of individuals. (D) Precision-recall curves 
comparing performance of Watershed, RIVER, and GAM (colors) using held-out pairs of 
individuals for three median outlier signals. (E) Symmetric heatmap showing learned tissue-
Watershed edge parameters (weights) between pairs of tissue outlier signals after training 
tissue-Watershed on eOutliers across single tissues. Tissue color to tissue name mapping can 
be found in fig. S21D. (F) Area under precision recall curves [AUC(PR); y-axis] in a single 
tissue between tissue-GAM, tissue-RIVER, and tissue-Watershed (x-axis) when applied to 
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outliers across single tissues in all three outlier signals (colors). Precision recall curves in 
each tissue were generated using held-out pairs of individuals.
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Fig. 5. Trait associations for RVs underlying outlier genes.
(A) Distribution of the number of outlier genes, outlier genes with a nearby RV, and genes 
with a high Watershed posterior variant per data type. We added one to all values so that 
individuals with 0 are included. (B) Distribution of effect sizes, transformed to a percentile, 
for the set of GTEx RVs that appear in UKBB and are not outlier variants, those that are 
outlier variants, and those outlier variants that fall in colocalizing genes for the matched trait 
across 34 traits. Percentiles were calculated on the set of rare GTEx variants that overlap 
UKBB. The set of genes was restricted to those with at least one outlier individual in any 
data type and a nearby variant included in the test set (4787 variants and 1323 genes). P 
values were calculated from a one-sided Wilcoxon rank-sum test. (C) Proportion of variants 
filtered by Watershed posterior that fell in the top 25% of effect sizes for a colocalized trait 
(red) and the proportion of randomly selected variants of an equal number that also fall in 
these regions over 1000 iterations (black). (D) Manhattan plot (top) across chromosome 9 
for asthma in the UKBB, filtered for non–low-confidence variants, with two high-Watershed 
variants, rs149045797 and rs146597587, shown in pink and the lead colocalized variant, 
rs3939286, shown in blue. The variants’ effect size ranks were similarly high for both self-
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reported and diagnosed asthma, but the summary statistics are shown for asthma diagnosis 
here. The UKBB MAF versus absolute value of the effect size for all variants within 10 kb 
of the Watershed variant is also shown (bottom). (E) Manhattan plot across chromosome 22 
for self-reported high cholesterol in the UKBB, filtered to remove low confidence variants, 
with the high-Watershed variant rs564796245 shown in pink. The UKBB MAF versus 
absolute value of the effect size for all variants within 10 kb of the Watershed variant is also 
shown (bottom).
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